The purpose of the COVID-19 vaccine is prevention. It can only reduce the chance of contracting the virus, but it cannot completely guarantee that you will not be infected.

Pharmaceutical efficacy experimental data can be clinical experimental data or animal experimental data, as long as it proves that it has corresponding therapeutic and preventive effects. You do not have to wait until the clinical experimental data are released before you can apply for a patent. The description of the invention patent application has disclosed relevant animal experiment data, which basically meets the conditions for sufficient disclosure of the description.

Extended information:

Notes:

The State Intellectual Property Office targets various patent applications or cases involving the prevention and treatment of COVID-19, such as COVID-19 treatment and prevention Protective products and methods such as protective drugs and vaccines, testing methods and instruments, masks, goggles, and disinfectants are subject to priority review upon request.

The content of this patent application involves technologies for the prevention and control of the new coronavirus epidemic, which falls under the circumstances that can be prioritized for review under the "Administrative Measures for Patent Priority Examination". It also complies with the relevant provisions of the Ten Articles on Resumption of Work and Production. After the applicant submits a priority examination request, the State Intellectual Property Office considers that it meets the priority examination standards and handles it according to the priority examination procedures.

Baidu Encyclopedia - New Coronavirus Vaccine

People's Daily Online - China's first new coronavirus vaccine patent approved